Takeda is expected to win conditional European Union antitrust approval for its $62 billion Shire acquisition, the last regulatory approval the company needs, Reuters reports.
Here's what you should know:
1. The approval will be contingent upon Takeda divesting Shire's gastrointestinal pipeline compound, Reuters reports. The compound overlaps with Takeda's own inflammatory bowel disease drug, Entyvio.
2. Entyvio is Takeda's biggest selling drug.
3. After earning EU approval, Takeda must earn shareholder approval.
4. Takeda scheduled a general meeting Dec. 5, to hold a shareholder vote, the Financial Times reports.
5. A portion of Takeda's shareholders are vocal opponents of the deal, buta past procedural vote on the deal passed with little resistance.